DK1124568T3 - Polyspecifikke bindingsmolekyler og anvendelser deraf - Google Patents
Polyspecifikke bindingsmolekyler og anvendelser derafInfo
- Publication number
- DK1124568T3 DK1124568T3 DK99970601T DK99970601T DK1124568T3 DK 1124568 T3 DK1124568 T3 DK 1124568T3 DK 99970601 T DK99970601 T DK 99970601T DK 99970601 T DK99970601 T DK 99970601T DK 1124568 T3 DK1124568 T3 DK 1124568T3
- Authority
- DK
- Denmark
- Prior art keywords
- binding molecules
- polyspecific binding
- chain
- molecules
- polyspecific
- Prior art date
Links
- 108091008874 T cell receptors Proteins 0.000 abstract 1
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Toxicology (AREA)
- General Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- Cell Biology (AREA)
- Pharmacology & Pharmacy (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Polysaccharides And Polysaccharide Derivatives (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Saccharide Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US10516498P | 1998-10-21 | 1998-10-21 | |
| PCT/US1999/024645 WO2000023087A1 (fr) | 1998-10-21 | 1999-10-21 | Molecules de liaison polyspecifiques et leurs utilisations |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK1124568T3 true DK1124568T3 (da) | 2008-01-02 |
Family
ID=22304401
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK99970601T DK1124568T3 (da) | 1998-10-21 | 1999-10-21 | Polyspecifikke bindingsmolekyler og anvendelser deraf |
Country Status (9)
| Country | Link |
|---|---|
| US (3) | US6534633B1 (fr) |
| EP (1) | EP1124568B1 (fr) |
| JP (1) | JP4467188B2 (fr) |
| AT (1) | ATE370967T1 (fr) |
| AU (1) | AU1218000A (fr) |
| DE (1) | DE69936927T2 (fr) |
| DK (1) | DK1124568T3 (fr) |
| ES (1) | ES2293748T3 (fr) |
| WO (1) | WO2000023087A1 (fr) |
Families Citing this family (66)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20030144474A1 (en) * | 2000-06-05 | 2003-07-31 | Sunol Molecular Corporation | T cell receptor fusions and conjugates and methods of use thereof |
| JP4447456B2 (ja) | 2001-06-05 | 2010-04-07 | アルトール バイオサイエンス コーポレーション | P53結合t細胞受容体分子とその使用 |
| EP1567553A2 (fr) * | 2002-12-03 | 2005-08-31 | Avidex Ltd. | Recepteurs |
| JP3803790B2 (ja) | 2003-02-17 | 2006-08-02 | 株式会社東北テクノアーチ | 新規なダイアボディ型二重特異性抗体 |
| US8772451B2 (en) | 2003-11-10 | 2014-07-08 | Altor Bioscience Corporation | Soluble TCR molecules and methods of use |
| US7964380B2 (en) * | 2005-01-21 | 2011-06-21 | Argylia Technologies | Nanoparticles for manipulation of biopolymers and methods of thereof |
| GB0507046D0 (en) * | 2005-04-06 | 2005-05-11 | Celltech R&D Ltd | Primers |
| US20080299137A1 (en) * | 2005-10-28 | 2008-12-04 | Novo Nordisk A/S | Fusion Proteins That Bind Effector Lymphocytes And Target Cells |
| WO2007085266A1 (fr) * | 2006-01-30 | 2007-08-02 | Dako Denmark A/S | Quantification ultra-rapide de lymphocytes-t spécifiques d'antigènes dans du sang entier par cytométrie de flux |
| EP2505209A1 (fr) | 2006-06-26 | 2012-10-03 | MacroGenics, Inc. | Anticorps spécifiques au FcgammaRIIB et procédés d'utilisation associés |
| FR2902799B1 (fr) | 2006-06-27 | 2012-10-26 | Millipore Corp | Procede et unite de preparation d'un echantillon pour l'analyse microbiologique d'un liquide |
| US20100210478A1 (en) * | 2006-06-29 | 2010-08-19 | Xiaolian Gao | Make and use of surface molecules of varied densities |
| US8569464B2 (en) | 2006-12-21 | 2013-10-29 | Emd Millipore Corporation | Purification of proteins |
| US8163886B2 (en) | 2006-12-21 | 2012-04-24 | Emd Millipore Corporation | Purification of proteins |
| US8362217B2 (en) | 2006-12-21 | 2013-01-29 | Emd Millipore Corporation | Purification of proteins |
| EP2361930A3 (fr) | 2007-03-26 | 2011-10-26 | Dako Denmark A/S | Multimeres du complexes peptide-cmh et leur utilisation dans des maladies infectieuses de borrelia |
| EP2167537A2 (fr) | 2007-07-03 | 2010-03-31 | Dako Denmark A/S | Procedes compiles pour analyser et trier des echantillons |
| WO2009039854A2 (fr) | 2007-09-27 | 2009-04-02 | Dako Denmark A/S | Multimères cmh dans le diagnostic, le vaccin et le traitement de la tuberculose |
| US10968269B1 (en) | 2008-02-28 | 2021-04-06 | Agilent Technologies, Inc. | MHC multimers in borrelia diagnostics and disease |
| US20110070191A1 (en) * | 2008-03-19 | 2011-03-24 | Wong Hing C | T cell receptor fusions and conjugates and methods of use there of |
| WO2009151514A1 (fr) * | 2008-06-11 | 2009-12-17 | Millipore Corporation | Bioréacteur à cuve agitée |
| CN104800147A (zh) * | 2008-07-10 | 2015-07-29 | 德勒尼克斯治疗股份公司 | 用于大分子的增强的递送的方法和组合物 |
| WO2010009735A2 (fr) * | 2008-07-23 | 2010-01-28 | Dako Denmark A/S | Analyse et réparation combinatoires |
| GB0817244D0 (en) * | 2008-09-20 | 2008-10-29 | Univ Cardiff | Use of a protein kinase inhibitor to detect immune cells, such as T cells |
| US11992518B2 (en) | 2008-10-02 | 2024-05-28 | Agilent Technologies, Inc. | Molecular vaccines for infectious disease |
| US10369204B2 (en) | 2008-10-02 | 2019-08-06 | Dako Denmark A/S | Molecular vaccines for infectious disease |
| ES2749232T3 (es) * | 2008-12-16 | 2020-03-19 | Emd Millipore Corp | Reactor de tanque agitado y procedimiento |
| EP2258719A1 (fr) | 2009-05-19 | 2010-12-08 | Max-Delbrück-Centrum für Molekulare Medizin (MDC) | Récepteur de lymphocyte T à cibles multiples |
| GB0908613D0 (en) | 2009-05-20 | 2009-06-24 | Immunocore Ltd | T Cell Reseptors |
| SG10201804385YA (en) | 2010-05-17 | 2018-06-28 | Emd Millipore Corp | Stimulus responsive polymers for the purification of biomolecules |
| KR20130041843A (ko) * | 2010-06-08 | 2013-04-25 | 이엠디 밀리포어 코포레이션 | 바이오 분자의 정제에 사용되는 중합체의 잔량을 검출하는 방법 |
| AU2012316859A1 (en) * | 2011-09-29 | 2014-04-17 | Apo-T B.V. | Multi-specific binding molecules targeting aberrant cells |
| DK3369742T3 (da) | 2011-10-05 | 2020-10-19 | Univ Rockefeller | Dimere bakteriofaglysiner |
| KR101963230B1 (ko) | 2011-12-26 | 2019-03-29 | 삼성전자주식회사 | 복수개의 단일 항체를 포함하는 단백질 복합체 |
| EP2802356A1 (fr) | 2012-01-13 | 2014-11-19 | Apo-T B.V. | Immunoglobulines restreintes à une cellule aberrante dotées d'une fraction toxique |
| UA114108C2 (uk) | 2012-07-10 | 2017-04-25 | Борд Оф Ріджентс, Дзе Юніверсіті Оф Техас Сістем | Моноклональне антитіло для застосування в діагностиці і терапії злоякісних пухлин і аутоімунного захворювання |
| US20150183877A1 (en) * | 2012-07-18 | 2015-07-02 | Eli Lilly And Company | Multi-Specific IgG-(Fab)2 Constructs Containing T-Cell Receptor Constant Domains |
| KR101911438B1 (ko) * | 2012-10-31 | 2018-10-24 | 삼성전자주식회사 | 이중 특이 항원 결합 단백질 복합체 및 이중 특이 항체의 제조 방법 |
| US20150320799A1 (en) | 2012-12-20 | 2015-11-12 | Purdue Research Foundation | Chimeric antigen receptor-expressing t cells as anti-cancer therapeutics |
| EP3071594A4 (fr) | 2013-11-22 | 2017-05-03 | The Board of Trustees of the University of Illionis | Récepteurs modifiés de haute affinité pour les lymphocytes t humains |
| US10816554B2 (en) * | 2014-04-04 | 2020-10-27 | The Board Of Trustees Of The Leland Stanford Junior University | Ligand discovery for T cell receptors |
| US9884921B2 (en) | 2014-07-01 | 2018-02-06 | Pfizer Inc. | Bispecific heterodimeric diabodies and uses thereof |
| JP7282521B2 (ja) | 2016-04-08 | 2023-05-29 | パーデュー・リサーチ・ファウンデイション | Car t細胞療法のための方法および組成物 |
| US11827688B2 (en) | 2016-06-02 | 2023-11-28 | Immunocore Limited | Dosing regimen for GP100-specific TCR—anti-CD3 SCFV fusion protein |
| EP3579870A4 (fr) | 2017-02-07 | 2020-12-30 | Seattle Children's Hospital (DBA Seattle Children's Research Institute) | Agents de ciblage de tumeur à lymphocytes t car (ctct) d'éther de phospholipide (ple) |
| CN110944651A (zh) | 2017-02-08 | 2020-03-31 | 蜻蜓疗法股份有限公司 | 用于自然杀伤细胞激活的多特异性结合蛋白及其治疗癌症的治疗性用途 |
| ES2955074T3 (es) | 2017-02-20 | 2023-11-28 | Dragonfly Therapeutics Inc | Proteínas que se unen a HER2, NKG2D Y CD16 |
| WO2018160622A1 (fr) | 2017-02-28 | 2018-09-07 | Endocyte, Inc. | Compositions et méthodes de thérapie par lymphocytes t car |
| WO2018166589A1 (fr) | 2017-03-15 | 2018-09-20 | Biontech Cell & Gene Therapies Gmbh | Récepteurs d'antigènes et leurs utilisations |
| WO2019046818A1 (fr) | 2017-09-01 | 2019-03-07 | Dana-Farber Cancer Institute, Inc. | Peptides immunogènes spécifiques des antigènes bcma et taci pour le traitement du cancer |
| AU2019209432A1 (en) | 2018-01-22 | 2020-08-06 | Seattle Children's Hospital (dba Seattle Children's Research Institute) | Methods of use for CAR T cells |
| CN111936518A (zh) | 2018-02-06 | 2020-11-13 | 西雅图儿童医院(Dba西雅图儿童研究所) | 对fl-ple标记的肿瘤表现出最佳的t细胞功能的荧光素特异性car |
| CA3090236A1 (fr) | 2018-02-08 | 2019-08-15 | Dragonfly Therapeutics, Inc. | Polytherapie de cancer impliquant des proteines de liaison multi-specifiques qui activent des cellules tueuses naturelles |
| SG11202007482WA (en) | 2018-02-08 | 2020-09-29 | Dragonfly Therapeutics Inc | Antibody variable domains targeting the nkg2d receptor |
| KR102832460B1 (ko) | 2018-02-20 | 2025-07-11 | 드래곤플라이 쎄라퓨틱스, 인크. | Cd33, nkg2d, 및 cd16에 결합하는 다중-특이적 결합 단백질, 및 이의 사용 방법 |
| WO2019165237A1 (fr) | 2018-02-23 | 2019-08-29 | Endocyte, Inc. | Procédé de séquençage pour thérapie par lymphocytes t à car |
| EA202091888A1 (ru) | 2018-08-08 | 2020-10-23 | Драгонфлай Терапьютикс, Инк. | Вариабельные домены антител, нацеленные на рецептор nkg2d |
| MX2021001527A (es) | 2018-08-08 | 2021-06-15 | Dragonfly Therapeutics Inc | Proteínas de unión a nkg2d, cd16 y a un antígeno asociado a tumor. |
| MA53293A (fr) | 2018-08-08 | 2021-11-17 | Dragonfly Therapeutics Inc | Protéines de liaison multi-spécifiques se liant à bcma, nkg2d et cd16, et méthodes d'utilisation |
| US12258373B2 (en) | 2018-12-17 | 2025-03-25 | Immudex Aps | Panel comprising Borrelia MHC multimers |
| CA3131138A1 (fr) | 2019-03-06 | 2020-09-10 | Dana-Farber Cancer Institute, Inc. | Recepteurs de lymphocytes t specifiques de l'antigene de maturation des lymphocytes b pour le traitement du cancer |
| MX2022013944A (es) | 2020-05-06 | 2022-11-30 | Dragonfly Therapeutics Inc | Proteinas que se unen al receptor activador de celulas asesinas naturales grupo 2 miembro d (nkg2d), cumulo de diferenciacion (cd16) y miembro a de la familia de dominios de lectina tipo c 12 (clec12a). |
| WO2022187539A1 (fr) | 2021-03-03 | 2022-09-09 | Dragonfly Therapeutics, Inc. | Méthodes de traitement du cancer à l'aide de protéines de liaison multi-spécifiques qui se lient à nkg2d, à cd16 et à un antigène associé à une tumeur |
| US12162940B2 (en) | 2021-05-05 | 2024-12-10 | Immatics Biotechnologies Gmbh | BMA031 antigen binding polypeptides |
| IL321737A (en) * | 2023-01-05 | 2025-08-01 | Angeles Therapeutics Inc | Methods and compositions for gene transformation and control of activity of synthetic and immune receptors |
| GB202320012D0 (en) * | 2023-12-22 | 2024-02-07 | Immunocore Ltd | Bispecific molecules |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3853515T3 (de) * | 1987-05-21 | 2005-08-25 | Micromet Ag | Multifunktionelle proteine mit vorbestimmter zielsetzung. |
| DE3920358A1 (de) * | 1989-06-22 | 1991-01-17 | Behringwerke Ag | Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung |
| ES2098368T3 (es) | 1990-08-09 | 1997-05-01 | Nat Jewish Ct Immun & Respirat | Produccion de anticuerpos monoclonales contra un elemento vbeta humano de los receptores de las celulas t, utilizando vectores de adn recombinante. |
| AU643109B2 (en) * | 1990-12-14 | 1993-11-04 | Cell Genesys, Inc. | Chimeric chains for receptor-associated signal transduction pathways |
| US5637481A (en) | 1993-02-01 | 1997-06-10 | Bristol-Myers Squibb Company | Expression vectors encoding bispecific fusion proteins and methods of producing biologically active bispecific fusion proteins in a mammalian cell |
| US6399368B1 (en) | 1992-01-17 | 2002-06-04 | Board Of Regents, The University Of Texas System | Secretion of T cell receptor fragments from recombinant Escherichia coli cells |
| CA2118508A1 (fr) | 1992-04-24 | 1993-11-11 | Elizabeth S. Ward | Production par recombinaison genetique de domaines semblables aux immunoglobulines dans les cellules procaryotes |
| FR2698880B1 (fr) | 1992-11-25 | 1995-02-24 | Inst Nat Sante Rech Med | Procédé de production de récepteurs T solubles, produits ainsi obtenus et leur utilisation dans des compositions diagnostiques ou thérapeutiques. |
| WO1996018105A1 (fr) * | 1994-12-06 | 1996-06-13 | The President And Fellows Of Harvard College | Recepteur de lymphocyte t monocatenaire |
| JPH11507843A (ja) * | 1996-03-28 | 1999-07-13 | ザ・ジョンズ・ホプキンス・ユニバーシティー | タンパク質の可溶性二価および多価ヘテロ二量体類縁体 |
| ATE533784T1 (de) * | 1997-10-02 | 2011-12-15 | Altor Bioscience Corp | Lösliche, einzelkettige proteine des t- zellrezeptors |
-
1999
- 1999-10-21 US US09/422,375 patent/US6534633B1/en not_active Expired - Lifetime
- 1999-10-21 AU AU12180/00A patent/AU1218000A/en not_active Abandoned
- 1999-10-21 AT AT99970601T patent/ATE370967T1/de active
- 1999-10-21 DE DE69936927T patent/DE69936927T2/de not_active Expired - Lifetime
- 1999-10-21 JP JP2000576861A patent/JP4467188B2/ja not_active Expired - Lifetime
- 1999-10-21 ES ES99970601T patent/ES2293748T3/es not_active Expired - Lifetime
- 1999-10-21 WO PCT/US1999/024645 patent/WO2000023087A1/fr not_active Ceased
- 1999-10-21 EP EP99970601A patent/EP1124568B1/fr not_active Expired - Lifetime
- 1999-10-21 DK DK99970601T patent/DK1124568T3/da active
-
2002
- 2002-11-05 US US10/287,941 patent/US8105830B2/en not_active Expired - Fee Related
-
2011
- 2011-12-22 US US13/335,362 patent/US20120230995A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| ATE370967T1 (de) | 2007-09-15 |
| DE69936927D1 (de) | 2007-10-04 |
| JP4467188B2 (ja) | 2010-05-26 |
| JP2004537952A (ja) | 2004-12-24 |
| WO2000023087A1 (fr) | 2000-04-27 |
| US8105830B2 (en) | 2012-01-31 |
| EP1124568B1 (fr) | 2007-08-22 |
| US6534633B1 (en) | 2003-03-18 |
| DE69936927T2 (de) | 2008-05-15 |
| ES2293748T3 (es) | 2008-03-16 |
| EP1124568A1 (fr) | 2001-08-22 |
| US20030171552A1 (en) | 2003-09-11 |
| US20120230995A1 (en) | 2012-09-13 |
| EP1124568A4 (fr) | 2003-08-27 |
| AU1218000A (en) | 2000-05-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK1124568T3 (da) | Polyspecifikke bindingsmolekyler og anvendelser deraf | |
| ATE533784T1 (de) | Lösliche, einzelkettige proteine des t- zellrezeptors | |
| CY1110689T1 (el) | Συνθεσεις οι οποιες περιλαμβανουν πολυπεπτιδια | |
| UA89017C2 (uk) | ЛЮДСЬКЕ АНТИТІЛО, ЩО СПЕЦИФІЧНО ЗВ'ЯЗУЄТЬСЯ З ЛЮДСЬКИМ TNFSF13b | |
| CY1110579T1 (el) | Η λειτουργια ενος υποδοχεα απτοσφαιρινης-αιμοσφαιρινης και οι χρησεις αυτου | |
| ATE276275T1 (de) | Mhc-komplexe und ihre verwendungen | |
| ATE187494T1 (de) | Multivalente einkettige antikörper | |
| CY1112101T1 (el) | Νευροτροφικοι παραγοντες | |
| SI1629011T1 (sl) | Humane molekule za vezavo anti hu cd | |
| NO20100580L (no) | Fremgangsmater for behandling av reumatoid artritt ved anvendelse av opploselig mutant CTLA4 molekyl | |
| DE60219419D1 (de) | Flt4 (vegfr-3) als ein ziel für krebs darstellung und anti-krebs-behandlung | |
| NO961706D0 (no) | Sammensetning som særlig binder seg til kolorektale kreftceller, samt fremgangsmåte for anvendelse av samme | |
| DE69942981D1 (de) | Flt4 (vegfr-3) als ziel für tumornachweis (imaging) und antitumortherapie | |
| NO981745L (no) | Monoklonalt antistoff BR110 og anvendelse av dette | |
| DK1479696T3 (da) | Humant monoklonalt antistof, der binder til Ep-CAM, og dets anvendelse ved cancerterapi | |
| MY112916A (en) | A conjugate between a modified superantigen and a target-seeking compound and the use of the conjugate | |
| ATE505208T1 (de) | Rezeptorbindende konjugate | |
| DE60228504D1 (de) | P53 bindende t-zellrezeptormoleküle und deren verwendungen | |
| EP1071443A4 (fr) | Peptides isoles correspondant a des sequences d'acides amines de ny-eso-1 qui se lient a des molecules mhc de classe i et mhc de classe ii, et leurs utilisations | |
| WO2003106649A3 (fr) | Test d'un conjugue et ses utilisations | |
| NO20053304L (no) | NOGO A bindingsmolekyler og farmasoytisk anvendelse av disse | |
| DK1121594T3 (da) | Fremgangsmåder til identifikation af hot-spot remanenser af bindende proteiner og små forbindelser som binder til samme | |
| NO20022441L (no) | Fremgangsmåter for å behandle Lupus basert på antistoffaffinitet og screeningsmetoder, og preparater foranvendelse av disse | |
| IL139571A0 (en) | A humanized antibody that binds to verotoxin, methods for the production thereof and pharmaceutical compositions containing the same | |
| EA200400384A1 (ru) | Растворимый рецептор т-клетки |